Challenges in the sequencing of therapies for the management of metastatic castration-resistant prostate cancer

Phillip Parente*, Francis Parnis, Howard Gurney

*Corresponding author for this work

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Prior to 2010, docetaxel was the standard option for chemotherapy in men with metastatic castration-resistant prostate cancer (mCRPC). Today, the picture is vastly different: several additional therapies have each demonstrated a survival benefit such that we now have chemotherapy (cabazitaxel), androgen suppressive agents (abiraterone acetate and enzalutamide), a cellular vaccine (sipuleucel-T) and radium-233 (for symptomatic bone metastases). With several other agents in the pipeline for late-stage disease, the future looks promising for mCRPC. As the available data are not able to inform as to the optimum sequencing of therapy, this remains a challenge. This paper draws on insights from published and ongoing clinical studies to provide a practical patient-focused approach to maximize the benefits of the current therapeutic armamentarium. Preliminary sequencing suggestions are made based on clinical trial criteria. But until more data become available, clinical gestalt, experience, cost and individual patient preferences will continue to drive choices.

Original languageEnglish
Pages (from-to)205-215
Number of pages11
JournalAsia-Pacific Journal of Clinical Oncology
Volume10
Issue number3
DOIs
Publication statusPublished - 2014
Externally publishedYes

Keywords

  • Abiraterone acetate
  • Cabazitaxel
  • Enzalutamide
  • Innovative therapy
  • Prostate cancer

Fingerprint Dive into the research topics of 'Challenges in the sequencing of therapies for the management of metastatic castration-resistant prostate cancer'. Together they form a unique fingerprint.

  • Cite this